JOURNAL SCANS

Our oncology experts identify the most important cancer-related articles from leading medical journals.

Page 1 of 165

« start ‹ previous ... 1 2 3 4 5 ... next › end »

Management of Stage I Seminomatous Testicular Cancer: A Systematic Review

P Chung, LA Mayhewy, P Warde, E Winquistz, H Lukka, on behalf of the Genitourinary Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care, 2010 Feb 1, Clin Oncol

Since virtually all patients with stage I testicular seminoma are cured, surveillance seems to be the preferred option for management, as it minimizes the toxicity that can result from adjuvant treatm... The...

Management of Stage I Non-Seminomatous Testicular Cancer: A Systematic Review and Meta-analysis

SJ Hotte, LA Mayhew, M Jewett, J Chin, E Winquist, on behalf of the Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care, 2010 Feb 1, Clin Oncol

For patients with stage I non-seminomatous testicular cancer, excellent cure rates are attained with all management options (surveillance, adjuvant chemotherapy, or retroperitoneal lymphadenectomy). Although... After...

Prognostic Nomogram for Overall Survival in Stage IIB-IVA Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy

J-Y Tseng, M-S Yen, N-F Twu, C-R Lai, H-C Horng, C-C Tseng, K-C Chao, C-M Juang, 2010 Feb 1, Am J Obstet Gynecol

A nomogram for predicting 5-year survival may be useful for counseling patients with cervical cancer. Objective: On the basis of outcome data from concurrent chemoradiotherapy (CCRT) for locally advanced...

Efficacy of Chemotherapy With Carboplatin and Paclitaxel for Unresectable Thymic Carcinoma

S Igawa, H Murakami, T Takahashi, Y Nakamura, A Tsuya, T Naito, K Kaira, A Ono, T Shukuya, A Tamiya, M Endo, N Yamamoto, 2010 Feb 1, Lung Cancer

This retrospective review in 11 patients with unresectable thymic carcinoma found that paclitaxel plus carboplatin was an effective therapy, with acceptable toxicity. Background: Thymic carcinoma is a...

Gamma Knife Radiosurgery as a Therapeutic Strategy for Intracranial Sarcomatous Metastases

T Flannery, H Kano, A Niranjan, EA Monaco III, JC Flickinger, J Kofler, LD Lunsford, D Kondziolka, 2010 Feb 1, Int J Radiat Oncol Biol Phys

The majority of intracranial sarcomatous metastases have reasonable radiosensitivity to SRS. Gamma Knife radiosurgery may be a good alternative to surgery in selected cases. Purpose: To determine the...

Neoadjuvant Chemotherapy With Trastuzumab Followed by Adjuvant Trastuzumab Versus Neoadjuvant Chemotherapy Alone, in Patients With HER2-Positive Locally Advanced Breast Cancer (the NOAH Trial)

L Gianni, W Eiermann, V Semiglazov, A Manikhas, A Lluch, S Tjulandin, M Zambetti, F Vazquez, M Byakhow, M Lichinitser, MA Climent, E Ciruelos, B Ojeda, M Mansutti, A Bozhok, R Baronio, A Feyereislova, C Barton, P Valagussa, J Baselga, 2010 Jan 30, Lancet

EXPERT COMMENTARY

Addition of neoadjuvant and adjuvant trastuzumab to neoadjuvant chemotherapy improved event-free survival and tumor response rates in women with HER2-positive locally advanced or inflammatory breast c... Background:...

Neoadjuvant Capecitabine and Oxaliplatin Before Chemoradiotherapy and Total Mesorectal Excision in MRI-Defined Poor-Risk Rectal Cancer

YJ Chua, Y Barbachano, D Cunningham , JR Oates, G Brown, A Wotherspoon, D Tait, A Massey, NC Tebbutt, I Chau, 2010 Jan 26, Lancet

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

CN Sternberg, ID Davis, J Mardiak, C Szczylik, E Lee, J Wagstaff, CH Barrios, P Salman, OA Gladkov, A Kavina, JJ Zarbá, M Chen, L McCann, L Pandite, DF Roychowdhury, RE Hawkins, 2010 Jan 25, J Clin Oncol

In this randomized, double-blind, multinational, phase III study, pazopanib significantly improved both PFS and response rates when compared with placebo. Access this article » ...

Identification of an Alternative CD20 Transcript Variant in B Cell Malignancies Coding for a Novel Protein Associated to Rituximab Resistance

C Henry, M Deschamps, P-S Rohrlich, J-R Pallandre, J-P Rémy-Martin, M Callanan, A Traverse-Glehen, C GrandClément, F Garnache-Ottou, R Gressin, E Deconinck, G Salles, E Robinet, P Tiberghien, C Borg, C Ferrand, 2010 Jan 20, Blood

Detection of alternate splicing of CD20 mRNA yielded a novel ΔCD20 protein that is correlated with rituximab resistance. This alternative transcript may be an interesting diagnostic, prognostic, or predictive... Human...

Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era

AM Evens, KA David, I Helenowski, B Nelson, D Kaufman, SM Kircher, A Gimelfarb, E Hattersley, LA Mauro, B Jovanovic, A Chadburn, P Stiff, JN Winter, J Mehta, K Van Besien, S Gregory, LI Gordon, JM Shammo, SE Smith, SM Smith, 2010 Jan 19, J Clin Oncol

In this multicenter, retrospective analysis of 80 patients with post-transplant lymphoproliferative disorder (PTLD), addition of rituximab to first-line therapy with reduction of immunosuppression was... Access...

« start ‹ previous ... 1 2 3 4 5 ... next › end »

Page 1 of 165

Comment Print page RSS feeds

Editors' Choice

Neoadjuvant Trastuzumab improves event-free survival in HER2+ locally advanced or inflammatory breast cancer.

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.

Sign-up now ›